PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases-Reference-Cited by-同舟云学术

PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases

Published:2014-11-11 Issue:11 Volume:9 Page:e112148
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Martín-Sánchez Esperanza,Odqvist Lina,Rodríguez-Pinilla Socorro M.,Sánchez-Beato Margarita,Roncador Giovanna,Domínguez-González Beatriz,Blanco-Aparicio Carmen,García Collazo Ana M.,Cantalapiedra Esther González,Fernández Joaquín Pastor,Olmo Soraya Curiel del,Pisonero Helena,Madureira Rebeca,Almaraz Carmen,Mollejo Manuela,Alves F. Javier,Menárguez Javier,González-Palacios Fernando,Rodríguez-Peralto José Luis,Ortiz-Romero Pablo L.,Real Francisco X.,García Juan F.,Bischoff James R.,Piris Miguel A.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Molecular classification of T-cell lymphomas;L de Leval;Crit Rev Oncol Hematol,2009

2. Peripheral T-cell lymphoma;FM Foss;Blood,2011

3. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management;JO Armitage;Am J Hematol,2012

4. Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, et al.. (2014) Prognostic Factors, Prognostic Indices and Staging in Mycosis Fungoides and Sezary Syndrome: Where are we now? Br J Dermatol Epub ahead of print.

5. NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases;JD Pearson;J Signal Transduct,2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL;npj Precision Oncology;2024-07-20

2. Targeting Pim kinases in hematological cancers: molecular and clinical review;Molecular Cancer;2023-01-25

3. Proteomics and genomics of a monomorphic epitheliotropic intestinal T-cell lymphoma: An extremely rare case report and short review of literature;Medicine;2022-11-25

4. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors;Bioorganic Chemistry;2022-02

5. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors;ACS Medicinal Chemistry Letters;2021-11-02